文献速递瓣膜外科

主动脉瓣与二尖瓣手术中同期行外科消融治疗心房颤动:一项全国性人群队列研究

Surgical ablation for atrial fibrillation during aortic and mitral valve surgery: A nationwide population-based cohort study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-09-09

该研究基于韩国国民健康保险服务数据库2003至2018年数据,纳入17,247例术前心房颤动接受主动脉瓣/二尖瓣手术的成人患者,比较同期外科消融与未消融的结局。中位随访6.7年,消融组全因死亡和缺血性卒中或系统性栓塞发生率均低于未消融组;经逆概率治疗加权调整后,外科消融与全因死亡、缺血性卒中或系统性栓塞及心力衰竭住院风险降低相关。

要点

  • 在17,247例心房颤动患者中,8,716例(50.5%)接受同期外科消融,8,531例(49.5%)未接受。
  • 消融组全因死亡发生率2.7患者年 vs 未消融组4.1患者年(P < .001)。
  • 调整后外科消融与全因死亡风险降低相关(HR 0.86,95%CI 0.80-0.92)。

核心结论

  • 在接受主动脉瓣/二尖瓣手术的心房颤动患者中,同期外科消融与死亡率和血栓栓塞事件风险降低显著相关。

研究设计与样本

  • 基于韩国国民健康保险服务数据库2003至2018年行政医疗数据的全国性人群队列研究,纳入成人术前心房颤动接受主动脉瓣/二尖瓣置换或二尖瓣修复患者,按是否行同期外科消融分组比较结局。

主要发现

  • 共纳入17,247例患者,8,716例(50.5%)接受外科消融,8,531例(49.5%)未接受,中位随访6.7年(124,842.2患者年)。
  • 消融组全因死亡发生率2.7患者年 vs 未消融组4.1患者年(P < .001)。
  • 消融组缺血性卒中或系统性栓塞发生率0.9患者年 vs 未消融组1.3患者年(P < .001)。
  • 经逆概率治疗加权调整后,外科消融与全因死亡风险降低相关(HR 0.86,95%CI 0.80-0.92)。
  • 调整后外科消融与缺血性卒中或系统性栓塞风险降低相关(HR 0.62,95%CI 0.55-0.71),与心力衰竭住院风险降低相关(HR 0.87,95%CI 0.79-0.96)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is limited evidence on the effectiveness of surgical atrial fibrillation ablation in reducing mortality or thromboembolic events during aortic/mitral valve surgery. We evaluated the association of surgical ablation versus no ablation with risks of all-cause death and ischemic stroke or systemic embolization among patients with preoperative atrial fibrillation undergoing concomitant aortic valve or mitral valve surgery. METHODS: With the use of administrative healthcare datasets from the Korean National Health Insurance Service database between 2003 and 2018, adult patients with atrial fibrillation undergoing aortic/mitral valve replacement or mitral valve repair were enrolled, and their outcomes were compared according to the performance of concomitant surgical ablation. The primary end points were all-cause death and thromboembolic event of ischemic stroke or systemic embolization. RESULTS: Among 17,247 patients with atrial fibrillation undergoing aortic/mitral valve surgery, 8716 (50.5%) received surgical ablation, whereas 8531 (49.5%) did not. During a median follow-up of 6.7 years (124,842.2 patient-years), death was less in the ablation group than in the no-ablation group (2.7 vs 4.1 patient-years; P < .001). The incidence of ischemic stroke or systemic embolization was also lower in the ablation group (0.9 vs 1.3 patient-years; P < .001). After adjustment with inverse probability of treatment weighting, surgical ablation was associated with decreased risks of all-cause death (hazard ratio, 0.86; 95% confidence interval, 0.80-0.92), ischemic stroke or systemic embolization (hazard ratio, 0.62; 95% confidence interval, 0.55-0.71), and hospitalization from heart failure (hazard ratio, 0.87; 95% confidence interval, 0.79-0.96). CONCLUSIONS: In patients with atrial fibrillation undergoing aortic/mitral valve surgery, concomitant surgical ablation was significantly associated with lower risks of mortality and thromboembolic events.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim HJ, Kim YJ, Kim M, et al. Surgical ablation for atrial fibrillation during aortic and mitral valve surgery: A nationwide population-based cohort study. J Thorac Cardiovasc Surg. 2022. PMID: 36202664. doi:10.1016/j.jtcvs.2022.08.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。